myirislogo
17 September, 2019 11:45 IST
My Last 5 Scrips
Company BSE Price (Rs) % Chg
Tata Motors 127.00 1.21
Tata Stl 359.80 0.37
State Bank O 281.95 0.95
Ong Corp 131.40 0.61
Icici Bank 410.15 0.44
Clear All Clear Last
   
NSE Live
Nifty Live Prices
Top Gainers/Losers
Top 10 Turnover
No Delivery Stocks
Advances / Declines new
Index Weightage new
Exchange Holidays new
Nse Sectors new
Contribution To Index new
Bonus new
Rights new
Delisted-Shares new
Split of Value new
BSE Live
BSE30 Live Prices
Top Gainers/Losers
Top 10 Turnover
No Delivery Stocks
Advances / Declines new
Index Weightage new
Exchange Holidays new
Bse Sectors new
Contribution To Index new
Bonus new
Rights new
Delisted-Shares new
Split of Value new
Market Pulse
Leaders
Laggards
FII Activity
Mutual Fund Activity
Meetings
Results Watch
Results Calendar
Results Announced
Watch
Sector Watch
Economy Watch
Company
Snapshots
Quotes
Charts
Financials
Recent News
Broker Research
Meetings
Research Tutorial
Research
Research Reports
Snapshot-Aurobindo Pharma Limited
Aurobindo Pharma Limited
Sector:Pharmaceuticals Pharmaceuticals - Bulk Drugs
BSE:524804NSE:AUROPHARMABloomberg:ARBP@INReuters:ARBN.BO
Market Lot: 1Face Value: 1ISIN Demat: INE406A01037
QuotesSnapshotChartsFinancialsResearchRecent News
Peer GroupAGM/AMMF HoldingDiscussion ForumBSE/NSE NoticesBSE/NSE Deals

 
 
Recent Developments
11-FEB-19 Aurobindo Pharma, a world-leading marketer and manufacturer of generic pharmaceuticals and active pharmaceutical ingredients, today announced that it has closed the acquisition of Apotex's commercial operations and certain supporting infrastructure in five European countries. 18-JAN-19 Aurobindo Pharma, announces the signing of a definitive agreement to acquire a portfolio of seven branded oncology injectable products from Spectrum p...   More..
Business Profile Future Plans
CEO Talk
Aurobindo Pharma, plans to complete restructuring and expansion programme during Q4 FY 2001-02. The company plans to achieve a turnover of above Rs 4,000 crore by FY 2005-06 with formulations accounting for 30 per cent. Joint ventures in US and China are expected boost the company`s international revenues.  Srinivas Lanka
One To One
Recent news
Latest News
Aurobindo Pharma to acquire portfolio of oncology injectables products  -IRIS 18-Jan-19
Previous

More


Brief Financials (in Rs. Mn.)Detailed Quarterly
Period ending (months)31-Mar-2016(12)31-Mar-2015 (12)31-Mar-2014 (12)
Net sales 89223.8080180.0070495.70
Other Income392.90423.20328.70
Total Income89616.7080603.2070824.40
Cost of goods sold67171.5058446.8051912.30
OPBDIT22445.2022156.4018912.10
PAT16196.7015163.4011720.90
Gross Block---
Equity capital585.20292.00291.50
EPS (Rs.)-52.0140.24
DPS (Rs.)---
BV (Rs.)---
P/E range (x)-9.80 - 24.593.44 - 13.54
Debt / Equity (x)---
Operating margin (% of OI)25.027.526.7
Net margin (% of OI)18.118.816.5
Detailed Financials
Income 
Statement
Balance Sheet Latest 
Quarterly/Halfyearly
Ratio Analysis Share Statistics
Price Charts
Scrip Information



Registered Office
ADDRESS
Plot No 2
Maitri Vihar
Ameerpet
Hyderabad
Andhra Pradesh-500 038
PHONE
(040) 6672 5000
FAX
(040) 2374 1080/ 6833
 
Board of Directors
NSE/BSE Announcements


Home | Shares | F&O | Mutual Funds | Loans | Insurance | News Centre
Wealth Tracker | Tax Corner | NRI Centre | Search in myiris | Advertise
All rights reserved. IRIS Business Services Limited
Disclaimer